Baker Bros. Advisors
Latest statistics and disclosures from Baker Bros. Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BGNE, INCY, ACAD, SMMT, MDGL, and represent 62.37% of Baker Bros. Advisors's stock portfolio.
- Added to shares of these 10 stocks: INSM (+$61M), CRSP (+$35M), SMMT (+$26M), IMVT (+$22M), Bicara Therapeutics (+$21M), PRAX (+$11M), REPL (+$11M), CNTA (+$11M), ARVN (+$10M), IONS (+$9.0M).
- Started 6 new stock positions in Aligos Therapeutics, ARVN, WVE, GPCR, IONS, Bicara Therapeutics.
- Reduced shares in these 10 stocks: Insmed Inc convertible security (-$56M), HOOK (-$32M), CERE (-$28M), ATHA (-$8.4M), TLIS, ADAP, SAGE, ACHL, ALGS, NAMS.
- Sold out of its positions in ACHL, ADAP, ALGS, ATHA, CERE, Insmed Inc convertible security, SAGE, TLIS.
- Baker Bros. Advisors was a net buyer of stock by $105M.
- Baker Bros. Advisors has $9.6B in assets under management (AUM), dropping by 23.31%.
- Central Index Key (CIK): 0001263508
Tip: Access up to 7 years of quarterly data
Positions held by Baker Bros. Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Baker Bros. Advisors
Baker Bros. Advisors holds 93 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| BeiGene Sponsored Adr (BGNE) | 24.6 | $2.4B | 11M | 224.51 |
|
|
| Incyte Corporation (INCY) | 21.1 | $2.0B | 31M | 66.10 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 6.8 | $660M | 43M | 15.38 |
|
|
| Summit Therapeutics (SMMT) | 5.5 | $535M | +5% | 24M | 21.90 |
|
| Madrigal Pharmaceuticals (MDGL) | 4.3 | $419M | 2.0M | 212.22 |
|
|
| Revolution Medicines (RVMD) | 3.6 | $343M | 7.6M | 45.35 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 3.5 | $335M | 6.4M | 52.39 |
|
|
| Insmed Incorporated Com Par $.01 (INSM) | 3.3 | $322M | +23% | 4.4M | 73.00 |
|
| Kymera Therapeutics (KYMR) | 2.9 | $284M | 6.0M | 47.33 |
|
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 2.2 | $213M | 9.4M | 22.63 |
|
|
| Edgewise Therapeutics (EWTX) | 1.6 | $156M | 5.8M | 26.69 |
|
|
| Replimune Group (REPL) | 1.3 | $121M | +9% | 11M | 10.96 |
|
| Alkermes SHS (ALKS) | 1.2 | $117M | 4.2M | 27.99 |
|
|
| Denali Therapeutics (DNLI) | 1.1 | $109M | 3.7M | 29.13 |
|
|
| Insmed Incorporated Note 0.75% 6/1/2028 (Principal) | 1.0 | $98M | 43M | 2.29 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 0.9 | $88M | +7% | 1.6M | 55.55 |
|
| Nurix Therapeutics (NRIX) | 0.9 | $87M | 3.9M | 22.47 |
|
|
| Entrada Therapeutics (TRDA) | 0.8 | $78M | 4.9M | 15.98 |
|
|
| Immatics SHS (IMTX) | 0.8 | $74M | 6.4M | 11.41 |
|
|
| Abcellera Biologics (ABCL) | 0.7 | $72M | 28M | 2.60 |
|
|
| Kiniksa Pharmaceuticals International Ord Shs Cl A (KNSA) | 0.7 | $70M | 2.8M | 24.99 |
|
|
| Igm Biosciences (IGMS) | 0.7 | $68M | 4.1M | 16.54 |
|
|
| argenx SE Sponsored Adr (ARGX) | 0.6 | $61M | 112k | 542.08 |
|
|
| Stoke Therapeutics (STOK) | 0.6 | $54M | 4.4M | 12.29 |
|
|
| Immunocore Holdings Ads (IMCR) | 0.5 | $47M | 1.5M | 31.13 |
|
|
| Kodiak Sciences (KOD) | 0.5 | $45M | 17M | 2.61 |
|
|
| Sera Prognostics Class A Com (SERA) | 0.4 | $42M | 5.4M | 7.80 |
|
|
| CRISPR Therapeutics Namen Akt (CRSP) | 0.4 | $40M | +743% | 843k | 46.98 |
|
| Xenon Pharmaceuticals (XENE) | 0.4 | $39M | 994k | 39.37 |
|
|
| Immunovant (IMVT) | 0.4 | $35M | +163% | 1.2M | 28.51 |
|
| Cerus Corporation (CERS) | 0.4 | $34M | 20M | 1.74 |
|
|
| Ideaya Biosciences (IDYA) | 0.3 | $34M | 1.1M | 31.68 |
|
|
| Roivant Sciences SHS (ROIV) | 0.3 | $32M | 2.8M | 11.54 |
|
|
| Akero Therapeutics (AKRO) | 0.3 | $32M | 1.1M | 28.69 |
|
|
| Krystal Biotech (KRYS) | 0.3 | $31M | 170k | 182.03 |
|
|
| Celcuity (CELC) | 0.3 | $28M | 1.9M | 14.91 |
|
|
| Monte Rosa Therapeutics (GLUE) | 0.3 | $26M | 4.9M | 5.30 |
|
|
| Dyne Therapeutics (DYN) | 0.3 | $24M | 672k | 35.92 |
|
|
| Biomea Fusion (BMEA) | 0.2 | $21M | 2.1M | 10.10 |
|
|
| Bicara Therapeutics | 0.2 | $21M | NEW | 833k | 25.47 |
|
| Prelude Therapeutics (PRLD) | 0.2 | $21M | 10M | 2.07 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.2 | $20M | +123% | 1.2M | 15.99 |
|
| Neurogene (NGNE) | 0.2 | $19M | 456k | 41.96 |
|
|
| Praxis Precision Medicines I (PRAX) | 0.2 | $19M | +145% | 323k | 57.54 |
|
| Alumis (ALMS) | 0.2 | $17M | 1.6M | 10.68 |
|
|
| Merus N V (MRUS) | 0.2 | $15M | 300k | 49.96 |
|
|
| Tscan Therapeutics (TCRX) | 0.1 | $14M | 2.8M | 4.98 |
|
|
| Neumora Therapeutics (NMRA) | 0.1 | $14M | 1.0M | 13.21 |
|
|
| Xencor (XNCR) | 0.1 | $14M | +22% | 670k | 20.11 |
|
| 2seventy bio Common Stock (TSVT) | 0.1 | $12M | 2.5M | 4.72 |
|
|
| Fate Therapeutics (FATE) | 0.1 | $11M | 3.0M | 3.50 |
|
|
| Arvinas Ord (ARVN) | 0.1 | $10M | NEW | 406k | 24.63 |
|
| Sana Biotechnology (SANA) | 0.1 | $9.9M | 2.4M | 4.16 |
|
|
| Design Therapeutics (DSGN) | 0.1 | $9.4M | +2% | 1.7M | 5.38 |
|
| Ionis Pharmaceuticals (IONS) | 0.1 | $9.0M | NEW | 224k | 40.06 |
|
| Opthea Sponsored Ads (OPT) | 0.1 | $8.8M | 2.2M | 4.07 |
|
|
| Celldex Therapeutics (CLDX) | 0.1 | $8.4M | 248k | 33.99 |
|
|
| Relay Therapeutics (RLAY) | 0.1 | $8.2M | 1.2M | 7.08 |
|
|
| Verve Therapeutics (VERV) | 0.1 | $8.2M | 1.7M | 4.84 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.1 | $8.0M | 4.0M | 2.01 |
|
|
| Mirum Pharmaceuticals (MIRM) | 0.1 | $7.4M | 191k | 39.00 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 0.1 | $6.0M | 313k | 19.14 |
|
|
| Tango Therapeutics (TNGX) | 0.1 | $5.8M | 750k | 7.70 |
|
|
| Skye Bioscience (SKYE) | 0.1 | $5.6M | +186% | 1.4M | 3.91 |
|
| Vaxcyte (PCVX) | 0.1 | $5.6M | 49k | 114.27 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 0.1 | $5.3M | 104k | 51.10 |
|
|
| DBV Technologies Sponsored Adr (DBVT) | 0.1 | $5.1M | 7.3M | 0.70 |
|
|
| Kala Pharmaceuticals (KALA) | 0.1 | $5.1M | 891k | 5.70 |
|
|
| Generation Bio (GBIO) | 0.0 | $4.8M | +61% | 1.9M | 2.47 |
|
| Alector (ALEC) | 0.0 | $4.3M | 927k | 4.66 |
|
|
| Prime Medicine (PRME) | 0.0 | $4.0M | 1.0M | 3.87 |
|
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.0 | $3.8M | 1.4M | 2.77 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.0 | $3.8M | NEW | 86k | 43.89 |
|
| Arcturus Therapeutics Hldg I (ARCT) | 0.0 | $3.5M | 151k | 23.21 |
|
|
| Hookipa Pharma (HOOK) | 0.0 | $3.5M | -90% | 813k | 4.30 |
|
| Leap Therapeutics (LPTX) | 0.0 | $3.0M | 1.2M | 2.57 |
|
|
| Enliven Therapeutics (ELVN) | 0.0 | $2.9M | 115k | 25.54 |
|
|
| Compass Therapeutics (CMPX) | 0.0 | $2.9M | 1.6M | 1.84 |
|
|
| Wave Life Sciences SHS (WVE) | 0.0 | $2.8M | NEW | 344k | 8.20 |
|
| Mersana Therapeutics (MRSN) | 0.0 | $2.1M | 1.1M | 1.89 |
|
|
| NewAmsterdam Pharma Company Ordinary Shares (NAMS) | 0.0 | $1.6M | 97k | 16.60 |
|
|
| Century Therapeutics (IPSC) | 0.0 | $1.4M | 798k | 1.71 |
|
|
| vTv Therapeutics Cl A (VTVT) | 0.0 | $1.3M | 97k | 13.56 |
|
|
| Aerovate Therapeutics (AVTE) | 0.0 | $1.3M | 629k | 2.09 |
|
|
| Pfizer (PFE) | 0.0 | $1.0M | 35k | 28.94 |
|
|
| Protara Therapeutics Com Stk (TARA) | 0.0 | $982k | 537k | 1.83 |
|
|
| Aligos Therapeutics | 0.0 | $719k | NEW | 83k | 8.66 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.0 | $576k | 76k | 7.60 |
|
|
| Pmv Pharmaceuticals (PMVP) | 0.0 | $480k | 322k | 1.49 |
|
|
| Foghorn Therapeutics (FHTX) | 0.0 | $419k | 45k | 9.31 |
|
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.0 | $370k | 53k | 7.00 |
|
|
| Tyra Biosciences (TYRA) | 0.0 | $249k | 11k | 23.51 |
|
|
| Surrozen W Exp 8/11/2026 (SRZNW) | 0.0 | $8.6k | 833k | 0.01 |
|
Past Filings by Baker Bros. Advisors
SEC 13F filings are viewable for Baker Bros. Advisors going back to 2010
- Baker Bros. Advisors 2024 Q3 filed Nov. 14, 2024
- Baker Bros. Advisors 2024 Q2 filed Aug. 14, 2024
- Baker Bros. Advisors 2024 Q1 filed May 15, 2024
- Baker Bros. Advisors 2023 Q4 filed Feb. 14, 2024
- Baker Bros. Advisors 2023 Q3 filed Nov. 14, 2023
- Baker Bros. Advisors 2023 Q2 filed Aug. 14, 2023
- Baker Bros. Advisors 2023 Q1 filed May 15, 2023
- Baker Bros. Advisors 2022 Q4 filed Feb. 14, 2023
- Baker Bros. Advisors 2022 Q3 filed Nov. 14, 2022
- Baker Bros. Advisors 2022 Q2 filed Aug. 15, 2022
- Baker Bros. Advisors 2022 Q1 filed May 16, 2022
- Baker Bros. Advisors 2021 Q4 filed Feb. 14, 2022
- Baker Bros. Advisors 2021 Q3 filed Nov. 15, 2021
- Baker Bros. Advisors 2021 Q2 filed Aug. 16, 2021
- Baker Bros. Advisors 2021 Q1 filed May 17, 2021
- Baker Bros. Advisors 2020 Q4 filed Feb. 16, 2021